Country: Canada
Language: English
Source: Health Canada
ENOXAPARIN SODIUM
SANDOZ CANADA INCORPORATED
B01AB05
ENOXAPARIN
150MG
SOLUTION
ENOXAPARIN SODIUM 150MG
INTRAVENOUS
15G/50G
Prescription
HEPARINS
Active ingredient group (AIG) number: 0131860002; AHFS:
APPROVED
2020-11-05
_Inclunox _ _Page 1 of 73_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr INCLUNOX ® Enoxaparin sodium solution for injection, 100 mg/mL 30 mg/0.3 mL 40 mg/0.4 mL 60 mg/0.6 mL 80 mg/0.8 mL 100 mg/mL (Subcutaneous or Intravenous Use Only) Pr INCLUNOX ® HP Enoxaparin sodium solution for injection, 150 mg/mL (High Potency) 120 mg/0.8 mL 150 mg/mL (Subcutaneous or Intravenous Use Only) Anticoagulant/Antithrombotic Agent Sandoz Canada Inc. 110 Rue de Lauzon Boucherville, Quebec J4B 1E6 Date of Initial Approval: November 5, 2020 Submission Control No: 233987 _ _ _Inclunox _ _Page 2 of 73_ TABLE OF CONTENTS TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................4 1 INDICATIONS ....................................................................................................................4 Pediatrics ..............................................................................................................................4 Geriatrics ..............................................................................................................................4 2 CONTRAINDICATIONS ..................................................................................................5 3 DOSAGE AND ADMINISTRATION ...............................................................................5 3.1 Dosing Considerations ...............................................................................................5 3.2 Recommended Dose and Dosage Adjustment ...........................................................5 3.3 Administration ...........................................................................................................8 3.4 Missed Dose .............................................................................................................10 4 OVERDOSAGE ........................................................ Read the complete document